Taxim is a No. 1 brand in cefotaxime market. Taxim injection is available in 4 strengths, 125 mg, 250 mg, 500 mg and 1 gm.
It works by inhibiting the bacterial cell wall synthesis. The action of cefotaxime reduces bacterial cell wall stability causing cell death. It has an added benefit, that it displays a resistance to penicillinases, a chemical produced by certain bacteria.
Hence, it is useful to treat infections that are resistant to penicillin antibiotics.
Taxim is indicated in the following conditions:
Bone and joint infections
Respiratory tract infections
Skin and skin structure infections
Central nervous system infections
Taxim is also used for pre-operative prophylaxis in patients undergoing surgical procedures.
Taxim is a brand of Alkem Laboratories, a leading Indian pharmaceutical company with global operations in more than 50 countries internationally. Alkem is engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products. Established in 1973, Alkem has a comprehensive portfolio of over 700 brands covering all the major therapeutic segments. Alkem has been ranked the No.1 Anti-infective company in India for the past 10 years
Taxim is prescribed in various Bacterial Infections. It is an antibiotic medication available in injectable form. It contains Cefotaxime that binds to 1 or more of the penicillin-binding proteins (PBPs) which inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. It is a broad spectrum antibiotic as it can be used to treat a wide variety of bacterial infections. It works by stopping the growth of the bacteria involved.
Bacterial Infections are caused due to bacteria which reproduce quickly in the body and may even release toxins which can damage tissues and make you very ill.
Bacterial Infections differ from other infections due to the microbes that cause them. Even though less than one percent of bacteria can make humans sick, bacterial infections can range from minor illnesses such as strep throat and ear infections to more life-threatening conditions like septicaemia.
Taxim has been known to work well among patients with mild to serious bacterial infection.
As directed by your physician
As directed by your physician
Adverse Reactions/ Side Effects
Rash (maculopapular or erythematous), pruritus, fever, eosinophilia; inflammation, phlebitis, thrombophlebitis (IV); pain, induration, tenderness at inj site (IM); anorexia, diarrhoea, nausea, vomiting, abdominal pain; transient neutropenia, granulocytopenia, leucopenia, eosinophilia or thrombocytopenia; transient increases in BUN and/or serum creatinine concentrations and interstitial nephritis; hepatitis, jaundice, cholestasis; transient increases in serum AST, ALT, LDH, γ-GT, bilirubin, and alkaline phosphatase concentrations; headache, agitation, confusion, fatigue, nocturnal perspiration. Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme.
Potentially Fatal: Clostridium difficile-associated diarrhoea and colitis, arrhythmias, anaphylaxis.
Warnings and Precautions
Patient w/ history of penicillin allergy and colitis. Renal impairment. Childn. Pregnancy and lactation. Monitoring Parameters Monitor renal function, CBC w/ differential. Observe for signs and symptoms of anaphylaxis during 1st dose.
Hypersensitivity to cefotaxime or other cephalosporins.
Symptoms: Elevations of BUN and creatinine. Risk of reversible encephalopathy. Management: Symptomatic and supportive treatment.
Parenteral: Store between 15-30°C.
Mechanism of Action
Cefotaxime binds to 1 or more of the penicillin-binding proteins (PBPs) which inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.